Jack W. Callicutt
2013
In 2013, Jack W. Callicutt earned a total compensation of $853.9K as Chief Financial Officer at Galectin Therapeutics.
Compensation breakdown
| Bonus | $39,803 |
|---|---|
| Option Awards | $709,542 |
| Salary | $87,500 |
| Other | $17,074 |
| Total | $853,919 |
Callicutt received $709.5K in option awards, accounting for 83% of the total pay in 2013.
Callicutt also received $39.8K in bonus, $87.5K in salary and $17.1K in other compensation.
Rankings
In 2013, Jack W. Callicutt's compensation ranked 7,327th out of 12,286 executives tracked by ExecPay. In other words, Callicutt earned more than 40.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,327 out of 12,286 | 40th |
Division Manufacturing | 2,629 out of 4,612 | 43rd |
Major group Chemicals And Allied Products | 817 out of 1,462 | 44th |
Industry group Drugs | 614 out of 1,156 | 47th |
Industry Pharmaceutical Preparations | 486 out of 890 | 45th |
Source: SEC filing on November 10, 2016.
Callicutt's colleagues
We found three more compensation records of executives who worked with Jack W. Callicutt at Galectin Therapeutics in 2013.
News
Galectin Therapeutics CEO Joel Lewis' 2023 pay slips 1% to $964K
December 3, 2024
Galectin Therapeutics CEO Joel Lewis' 2022 pay slips 17% to $974K
October 6, 2023
Galectin Therapeutics CEO Joel Lewis' 2021 pay jumps 55% to $1.2M
October 17, 2022
Galectin Therapeutics CEO Harold Shlevin's 2019 pay falls 25% to $1.3M
October 19, 2020